Compile Data Set for Download or QSAR
maximum 50k data
Found 108 of ph data with Target = 'Pro-glucagon'
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100827(US8507533, 138 | US8507533, 151 | US8507533, 374)
Affinity DataKi:  5.75nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100806(US8507533, 114 | US8507533, 115 | US8507533, 330)
Affinity DataKi:  7.60nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM142039(US8927577, 118 | US8927577, 20 | US8927577, 35)
Affinity DataKi:  14nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100806(US8507533, 114 | US8507533, 115 | US8507533, 330)
Affinity DataKi:  15.8nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100796(US8507533, 101)
Affinity DataKi:  17nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100827(US8507533, 138 | US8507533, 151 | US8507533, 374)
Affinity DataKi:  20.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM142041(US8927577, 22)
Affinity DataKi:  25nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100844(US8507533, 160 | US8507533, 398)
Affinity DataKi:  25.7nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100850(US8507533, 168)
Affinity DataKi:  27.4nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100852(US8507533, 170 | US8507533, 419)
Affinity DataKi:  28nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100844(US8507533, 160 | US8507533, 398)
Affinity DataKi:  29nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100822(US8507533, 129 | US8507533, 162 | US8507533, 399)
Affinity DataKi:  29.3nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100838(US8507533, 153)
Affinity DataKi:  32.3nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM160576(US9045389, 8)
Affinity DataKi:  33nM ΔG°:  -39.7kJ/molepH: 7.4 T: 2°CAssay Description:Full-length human GCGR (Accession Number: NM000160) subcloned into pcDNA3.1 was stably transfected into HEK293 cells (hGluc-1 HEK) and maintained und...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100837(US8507533, 152)
Affinity DataKi:  35.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM160577(US9045389, 9)
Affinity DataKi:  38nM ΔG°:  -39.4kJ/molepH: 7.4 T: 2°CAssay Description:Full-length human GCGR (Accession Number: NM000160) subcloned into pcDNA3.1 was stably transfected into HEK293 cells (hGluc-1 HEK) and maintained und...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100805(US8507533, 113)
Affinity DataKi:  38.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM142039(US8927577, 118 | US8927577, 20 | US8927577, 35)
Affinity DataKi:  39nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100861(US8507533, 188)
Affinity DataKi:  42.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100864(US8507533, 193)
Affinity DataKi:  44.7nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM160575(US9045389, 7)
Affinity DataKi:  45nM ΔG°:  -39.0kJ/molepH: 7.4 T: 2°CAssay Description:Full-length human GCGR (Accession Number: NM000160) subcloned into pcDNA3.1 was stably transfected into HEK293 cells (hGluc-1 HEK) and maintained und...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100815(US8507533, 122)
Affinity DataKi:  45.7nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100822(US8507533, 129 | US8507533, 162 | US8507533, 399)
Affinity DataKi:  47.3nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM2229(US8507533, 187 | US8507533, 448)
Affinity DataKi:  47.8nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM142042(US8927577, 23)
Affinity DataKi:  50nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100824(US8507533, 131)
Affinity DataKi:  51nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM142038(US8927577, 117 | US8927577, 19 | US8927577, 32)
Affinity DataKi:  53nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100801(US8507533, 109 | US8507533, 322)
Affinity DataKi:  57.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100826(US8507533, 133)
Affinity DataKi:  58nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM160583(US9045389, 18)
Affinity DataKi:  60nM ΔG°:  -38.3kJ/molepH: 7.4 T: 2°CAssay Description:Full-length human GCGR (Accession Number: NM000160) subcloned into pcDNA3.1 was stably transfected into HEK293 cells (hGluc-1 HEK) and maintained und...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100831(US8507533, 144)
Affinity DataKi:  62.6nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100829(US8507533, 140)
Affinity DataKi:  62.8nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100847(US8507533, 163)
Affinity DataKi:  65.9nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100797(US8507533, 105)
Affinity DataKi:  69.8nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100799(US8507533, 107)
Affinity DataKi:  71.6nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM142038(US8927577, 117 | US8927577, 19 | US8927577, 32)
Affinity DataKi:  74nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM142030(US8927577, 11 | US8927577, 30 | US8927577, 31)
Affinity DataKi:  76nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100856(US8507533, 181)
Affinity DataKi:  87.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100816(US8507533, 123)
Affinity DataKi:  88.4nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100830(US8507533, 141)
Affinity DataKi:  89.5nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM142035(US8927577, 16)
Affinity DataKi:  91nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100798(US8507533, 106)
Affinity DataKi:  91.9nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100794(US8507533, 300 | US8507533, 97 | US8507533, 98)
Affinity DataKi:  93nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100823(US8507533, 130 | US8507533, 369)
Affinity DataKi:  93.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100818(US8507533, 125)
Affinity DataKi:  98.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100854(US8507533, 176)
Affinity DataKi:  101nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM142030(US8927577, 11 | US8927577, 30 | US8927577, 31)
Affinity DataKi:  101nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100812(US8507533, 119)
Affinity DataKi:  103nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM142037(US8927577, 18)
Affinity DataKi:  109nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100817(US8507533, 124)
Affinity DataKi:  109nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 108 total ) | Next | Last >>
Jump to: